Novartis Aktie

118,30 EUR +0,90 EUR +0,77 %

07:34:43

STU

118,00 EUR -0,20 EUR -0,17 %

02.01.2026

GVIE

Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.224,13 Mrd. EUR

KGV17,02Div. Rendite3,95%

WKN904278

ISINCH0012005267

SymbolNVSEF

Novartis Aktien News

Sortieren:Datum Meistgelesen

17.04.24Dow JonesPress Release: Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sc...

15.04.24PR NewswireNew Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)

15.04.24GlobeNewswireNew Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)

15.04.24Dow JonesPress Release: New Novartis Fabhalta(R) -2-

15.04.24Dow JonesPress Release: New Novartis Fabhalta(R) (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus place...

11.04.24GlobeNewswireNovartis tender offer for MorphoSys AG commences

11.04.24Dow JonesPress Release: Novartis tender offer for -2-

11.04.24Dow JonesPress Release: Novartis tender offer for MorphoSys AG commences

06.04.24GlobeNewswireNew Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

06.04.24PR NewswireNew Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

22.03.24GlobeNewswireNovartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)

22.03.24Dow JonesPress Release: Novartis Fabhalta(R) (iptacopan) -2-

22.03.24Dow JonesPress Release: Novartis Fabhalta(R) (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglo...

05.03.24GlobeNewswireNovartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

04.03.24GlobeNewswireNovartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA

04.03.24Dow JonesPress Release: Novartis presents new data on -2-

04.03.24Dow JonesPress Release: Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier childr...

05.02.24GlobeNewswireNovartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash

05.02.24Dow JonesPress Release: Novartis to strengthen oncology -2-

05.02.24Dow JonesPress Release: Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash

31.01.24Dow JonesPress Release: Novartis delivers strong full year -5-

31.01.24GlobeNewswireNovartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts

31.01.24Dow JonesPress Release: Novartis delivers strong full year -4-

31.01.24Dow JonesPress Release: Novartis delivers strong full year -3-

31.01.24Dow JonesPress Release: Novartis delivers strong full year -2-

31.01.24Dow JonesPress Release: Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc(1)), with margin expansion. Continuing ...

19.01.24GlobeNewswireNovartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

19.01.24Dow JonesPress Release: Novartis Lutathera(R) significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gas...

08.01.24GlobeNewswireNovartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia

05.01.24GlobeNewswireNovartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis

05.01.24Dow JonesPress Release: Novartis expands production of Pluvicto(TM) with addition of its largest and most advanced radioligand therapy manufacturing facility in India...

11.12.23GlobeNewswireNovartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

11.12.23Dow JonesPress Release: Novartis investigational iptacopan -2-

11.12.23Dow JonesPress Release: Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in p...

11.12.23PR NewswireNovartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)

11.12.23GlobeNewswireNovartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)

11.12.23Dow JonesPress Release: Novartis presents new 48-week -3-

11.12.23Dow JonesPress Release: Novartis presents new 48-week -2-

11.12.23Dow JonesPress Release: Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta(R) (iptacopan...

08.12.23GlobeNewswireLatest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.